Basal insulin ameliorates post-breakfast hyperglycemia via suppression of post-breakfast proinsulin/C-peptide ratio and fasting serum free fatty acid levels in patients with type 2 diabetes

[1] Monnier L(2003)Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) Diabetes Care 26 881-885

[2] Lapinski H(2010)Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c Endocr J 57 259-266

[3] Colette C(2020)Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020 Diabetes Care 43 S98-S110

[4] Kikuchi K(2015)Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes Diabetes Care 38 503-512

[5] Nezu U(2010)Dose-response effects of insulin glargine in type 2 diabetes Diabetes Care 33 1555-1560

[6] Shirakawa J(2005)Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 28 254-259

[7] Sato K(2011)Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes Diabetes Care 34 2508-2514

[8] Togashi Y(2012)Design of the novel protraction mechanism of insulin degludec, an ultralong acting basal insulin Pharm Res 29 2104-2114

[9] Kikuchi T(2015)Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus Ther Adv Chronic Dis 6 375-388

[10] Aoki K(2015)Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Insulin Degludec and Insulin Glargine Expert Opin Drug Metab Toxicol 11 1193-1201

[1] Monnier L(2003)Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) Diabetes Care 26 881-885

[2] Lapinski H(2010)Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c Endocr J 57 259-266

[3] Colette C(2020)Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020 Diabetes Care 43 S98-S110

[4] Kikuchi K(2015)Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes Diabetes Care 38 503-512

[5] Nezu U(2010)Dose-response effects of insulin glargine in type 2 diabetes Diabetes Care 33 1555-1560

[6] Shirakawa J(2005)Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 28 254-259

[7] Sato K(2011)Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes Diabetes Care 34 2508-2514

[8] Togashi Y(2012)Design of the novel protraction mechanism of insulin degludec, an ultralong acting basal insulin Pharm Res 29 2104-2114

[9] Kikuchi T(2015)Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus Ther Adv Chronic Dis 6 375-388

[10] Aoki K(2015)Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Insulin Degludec and Insulin Glargine Expert Opin Drug Metab Toxicol 11 1193-1201